Read Sequencing Grows Fastest as Clinical Oncology Testing and Genomics Programs Expand, While Fragmented Reimbursement and Lab Capacity Limits Slow AdoptionDublin, Oct. (GLOBE NEWSWIRE) -- "NGS Kits ...
Illumina, Inc. introduced three early-access capabilities on its BioInsight Platform that help researchers move faster from sequencing data to discovery. BioInsight Platform Workflow Orchestrator ...
Illumina has introduced three early-access software capabilities on its BioInsight Platform designed to automate informatics ...
DRAGEN Ultra, BioInsight Platform Workflow Orchestrator, and BioInsight Platform Learning Cohorts are now available in early ...
Software, genome sequencing, drug discovery and cloud platforms lead adoption, while precision medicine, diagnostics and AI-enabled services create new opportunities.Dublin, Oct. 19, 2026 (GLOBE ...
Illumina on October 14, 2026 debuted the Illumina BioInsight Platform, which the company describes as its first unified ...
Rick Orford - Trading Stocks and Options For All on MSN
Why Illumina’s AI strategy could redefine its place in genomics
This video analyzes Illumina's effort to build an AI-driven data moat through its Billion Cell Atlas and the impact this ...
Here are 10 “Up & Comers” spatial biology companies that are not large enough to be ranked as public or private companies, ...
"Variant effect prediction tools, such as SpliceAI2, are among the key areas of focus for the BioInsight AI Lab," said Rami Mehio, senior vice president and general manager of BioInsight at Illumina. ...
Illumina, Inc. introduced SpliceAI2, a new genomic AI model designed to address one of the central challenges in genomics: understanding the functional consequences of genetic variation. SpliceAI2 ...
Shares of genomics company Illumina (NASDAQ: ILMN) jumped 7.7% in the afternoon session after Wall Street analysts lifted their price targets due to an expected improvement in clinical sales and new ...
Healthcare stocks underperformed the broader market in September, with the Health Care Select Sector SPDR Fund (XLV) falling 1.89% while the SPDR S&P 500 ETF Trust (SPY) gained 0.27%. Moderna (MRNA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results